文章：

循环细胞因子在化疗难治性结直肠癌中的预后价值

Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer

原文发布日期：13 December 2023

DOI: 10.3390/cancers15245823

类型: Article

开放获取: 是

英文摘要：

Circulating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (n= 85), 182 circulating cytokines were tested with a semi-quantitative multiplex assay, and prognostic cytokines were analyzed in the validation cohort (n= 111) by ELISA. Overall survival (OS) was the primary outcome measure, with the false discovery rate (FDR) method (significance level of <0.01) being used to correct for multiple comparisons. Four cytokines were associated with OS in the discovery cohort: insulin-like growth factor-binding protein 1 (IGFBP-1) (HR 2.1 [95%CI: 1.58–2.79], FDR < 0.001), insulin-like growth factor-binding protein 2 (IGFBP-2) (HR 1.65 [95%CI: 1.28–2.13], FDR = 0.006), serum amyloid A (SAA) (HR 1.84 [95%CI: 1.39–2.43], FDR < 0.001), and angiotensin II (HR 1.65 [95%CI: 1.29–2.1], FDR = 0.006). Of these, IGFBP-1 (HR 2.70 [95%CI: 1.56–4.76], FDR = 0.007) and IGFBP-2 (HR 3.33 [95%CI: 1.64–6.67], FDR = 0.008) were confirmed to be independently associated with OS in the validation cohort. Patients with high concentrations of IGFBP-1 and/or IGFBP-2 had a median OS of 3.0 months as compared with 6.9 months for those with low concentrations of both cytokines (HR 2.44 [95%CI: 1.52–4.0], FDR = 0.002) Validation of circulating IGFBP-1 and IGFBP-2 as independent prognostic biomarkers for chemorefractory CRC in larger, independent series is warranted.

摘要翻译： 

循环细胞因子可能是结直肠癌预后判断和治疗决策的理想生物标志物。本研究纳入了可获得血浆样本的化疗难治性结直肠癌患者。在发现队列（n=85）中，采用半定量多重检测法检测了182种循环细胞因子，并在验证队列（n=111）中通过酶联免疫吸附法分析了预后相关的细胞因子。总生存期为主要结局指标，采用错误发现率法（显著性水平<0.01）进行多重比较校正。在发现队列中，四种细胞因子与总生存期相关：胰岛素样生长因子结合蛋白1（风险比2.1[95%置信区间：1.58–2.79]，错误发现率<0.001）、胰岛素样生长因子结合蛋白2（风险比1.65[95%置信区间：1.28–2.13]，错误发现率=0.006）、血清淀粉样蛋白A（风险比1.84[95%置信区间：1.39–2.43]，错误发现率<0.001）和血管紧张素II（风险比1.65[95%置信区间：1.29–2.1]，错误发现率=0.006）。其中，胰岛素样生长因子结合蛋白1（风险比2.70[95%置信区间：1.56–4.76]，错误发现率=0.007）和胰岛素样生长因子结合蛋白2（风险比3.33[95%置信区间：1.64–6.67]，错误发现率=0.008）在验证队列中被证实与总生存期独立相关。胰岛素样生长因子结合蛋白1和/或胰岛素样生长因子结合蛋白2高浓度患者的中位总生存期为3.0个月，而两种细胞因子均为低浓度患者的中位总生存期为6.9个月（风险比2.44[95%置信区间：1.52–4.0]，错误发现率=0.002）。有必要在更大规模的独立队列中验证循环胰岛素样生长因子结合蛋白1和胰岛素样生长因子结合蛋白2作为化疗难治性结直肠癌独立预后生物标志物的价值。

原文链接：

Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer